Panacea Biotech's hepatitis B vaccine prequalified for accreditation by World Health Organization

By Lisa Kerner

Charlotte, N.C., Aug. 2 - Panacea Biotec Ltd. said it has received pre-qualification accreditation from the World Health Organization to supply recombinant hepatitis B vaccine to United Nations agencies.

The market for hepatitis B vaccine and its combinations is expected to reach 888 million doses, or $1 billion in revenues, in 2009, according to a company news release.

The World Health Organization and 116 countries have added the hepatitis B vaccine to their routine immunization programs.

Panacea is marketing its hepatitis B vaccine and combination vaccines through its joint venture company, Chiron Panacea Vaccines Put Ltd., under the brand names - ENIAC HB, Easy four (Hepatitis B + DPT) and Easy five (Hepatitis B + DTP + Hob).

Panacea Biotic is a health-management company based in New Delhi, India.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.